crisaborole

07/01/2023 - "However, in the key pivotal trials, a low proportion of the overall patient population was Asian, therefore the safety and efficacy of crisaborole in the Asian population with atopic dermatitis remains unclear. "
06/11/2020 - "Crisaborole was effective in treating mild-to-moderate atopic dermatitis based on ADSI and %BSA."
06/11/2020 - "Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area."
10/01/2019 - "Across races and ethnicities, crisaborole demonstrated efficacy for the treatment of mild-to-moderate atopic dermatitis, with a low frequency of treatment-related adverse events."
10/01/2019 - "Crisaborole treatment also improved atopic dermatitis signs/symptoms and quality of life. "

09/01/2021 - "Furthermore, a significantly greater proportion of patients treated with crisaborole achieved ISGA clear or almost clear at day 29 across all subgroups and demonstrated improvement in the Severity of Pruritus Scale score at week 4 versus patients treated with vehicle in most of the subgroups. "
07/01/2023 - "Crisaborole-treated patients showed a significantly greater reduction versus vehicle in change from baseline on the Peak Pruritus Numerical Rating Scale at week 4 (P = 0.0009). "
04/27/2018 - "Early improvement in pruritus required a score of none (0) or mild (1), with a ≥ 1-grade improvement from baseline on day 6. Significantly more patients experienced early improvement in pruritus with crisaborole than with vehicle (56.6% vs 39.5%; p< 0.001), including at earliest assessment (day 2, 34.3% vs 27.3%; p = 0.013). "
12/01/2017 - "Crisaborole, the newly approved medication, has relieved pruritus in more than one-third of patients within as little as 48 hours. "
09/01/2016 - "Crisaborole demonstrated a favorable safety profile and improvement in all measures of efficacy, including overall disease severity, pruritus, and other signs of AD."

03/01/2019 - "Here, we present two cases in which patients with psoriasis were treated successfully with crisaborole."
05/16/2014 - "In phase 2 studies, AN2728 had modest efficacy for psoriasis (40% of patients achieved a ≥ 2 grade improvement as assessed by the Overall target Plaque Severity Score). "
02/01/2020 - "Crisaborole maintains its dose-dependent effect in treatment of psoriasis and significantly reduces psoriatic plaques when compared to controls. "
03/01/2019 - "However, there is no current literature documenting use of crisaborole for psoriasis. "
03/01/2019 - "Treatment of psoriasis with crisaborole."

07/01/2023 - "Crisaborole-treated patients showed a significantly greater reduction versus vehicle in percentage change from baseline in Eczema Area and Severity Index total score at day 29 (P = 0.0002). "
03/01/2022 - "In two phase III clinical trials, eczema improved after 28 days of crisaborole use in patients aged ≥ 2 years. "
10/01/2021 - "In the study reported here we tested whether eczema improved with continuous crisaborole use after one to four back-to-back treatment periods, or 28–112 days. "
03/01/2022 - "We looked at whether traits of children aged 2–17 years affected how well crisaborole improved eczema. "
10/01/2021 - "Patients received crisaborole for the next 28-day period if they had eczema rashes. "

04/01/2016 - "Crisaborole also displayed topical anti-inflammatory activity in a skin inflammation model. "
04/01/2016 - "By inhibiting PDE4 and thus increasing levels of cAMP, crisaborole controls inflammation. "
01/01/2023 - "aureus skin colonization upon AD-like skin inflammation, which act as additional mechanisms by which crisaborole dampens the immunopathogenesis in mouse models of inflammatory skin diseases. "
01/01/2023 - "Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection."
01/01/2023 - "Furthermore, crisaborole was effective in reducing skin inflammation in the context of filaggrin deficiency. "